Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
ConditionNeoplasms
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorUSWM CT, LLC
About this trial
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Eligibility criteria
Qualifiers
Participants who have received at least one dose of ADP adoptive cell therapy agent.
Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Disqualifiers
None
Trial design
Treatments tested in this trial
- ADP adoptive cell therapy
Treatment groups
250 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov